Cancer’s future may lie in combination therapy—pairing treatments to outsmart tumors, boost survival, and bring new hope ...

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

The efficacy and safety of rivaroxaban monotherapy are consistent across all age groups of patients with atrial fibrillation and stable coronary artery disease, a study confirms.

Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased ...

They urge people to be wary of misinformation, like false claims on social media posts that hormones will prevent dementia ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Researchers found that adding a third immune-targeting drug to existing therapies helped shrink tumors in lab models of ...

A new study from Moffitt Cancer Center may offer a breakthrough for patients with advanced melanoma who don't respond to ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

In this video from the American Society of Retina Specialists annual meeting, Charles C. Wykoff, MD, PhD, FASRS, discusses ...

Being diagnosed with a disease like prostate cancer is a very impactful life event, making it vital to have people you love ...

Olutasidenib could dramatically extend survival and reduce dependence on transfusions for certain patients with myelodysplastic syndrome, according to results of a phase 1/2 investigation.Individuals ...